S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

GenMark Diagnostics Stock Forecast, Price & News

+0.77 (+4.15 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $19.34
50-Day Range
MA: $17.23
52-Week Range
Now: $19.34
Volume930,164 shs
Average Volume1.25 million shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
GenMark Diagnostics logo


GNMK Feb 2021 7.500 call
February 11, 2021 |  au.finance.yahoo.com
NTRA Apr 2021 160.000 call
January 28, 2021 |  uk.finance.yahoo.com
GNMK Feb 2021 20.000 call
January 17, 2021 |  au.finance.yahoo.com
GNMK Feb 2021 15.000 put
January 17, 2021 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:GNMK
Year FoundedN/A



Sales & Book Value

Annual Sales$88.02 million
Book Value$0.21 per share


Net Income$-47,350,000.00


Market Cap$1.41 billion
Next Earnings Date5/3/2021 (Estimated)


Overall MarketRank

1.40 out of 5 stars

Medical Sector

626th out of 1,972 stocks

Surgical & Medical Instruments Industry

66th out of 169 stocks

Analyst Opinion: 1.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.77 (+4.15 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

Is GenMark Diagnostics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GenMark Diagnostics stock.
View analyst ratings for GenMark Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than GenMark Diagnostics?

Wall Street analysts have given GenMark Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GenMark Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is GenMark Diagnostics' next earnings date?

GenMark Diagnostics is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for GenMark Diagnostics

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc. (NASDAQ:GNMK) issued its quarterly earnings results on Thursday, February, 25th. The medical equipment provider reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.04. GenMark Diagnostics had a negative net margin of 16.95% and a negative trailing twelve-month return on equity of 39.36%.
View GenMark Diagnostics' earnings history

How has GenMark Diagnostics' stock price been impacted by Coronavirus?

GenMark Diagnostics' stock was trading at $5.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNMK stock has increased by 256.8% and is now trading at $19.34.
View which stocks have been most impacted by COVID-19

What guidance has GenMark Diagnostics issued on next quarter's earnings?

GenMark Diagnostics updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $188-198 million, compared to the consensus revenue estimate of $182.47 million.

What price target have analysts set for GNMK?

4 Wall Street analysts have issued twelve-month price targets for GenMark Diagnostics' stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate GenMark Diagnostics' share price to reach $19.75 in the next twelve months. This suggests a possible upside of 2.1% from the stock's current price.
View analysts' price targets for GenMark Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the following people:
  • Mr. Scott Mendel, Pres & CEO (Age 54, Pay $506.61k)
  • Mr. John Frederick Ek, Chief Financial Officer (Age 45, Pay $423.71k)
  • Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 46, Pay $395.17k)
  • Mr. Abe Chohan, Sr. VP of Operations
  • Mr. Eric Stier, Sr. VP, Gen. Counsel & Sec. (Age 45)
  • Mr. Scott O'Brien, Sr. VP of Global Marketing & International Sales (Age 45)
  • Ms. Hollis Winkler, VP of HR (Age 46)
  • Mr. Michael John Harkins, Sr. VP of Sales (Age 56)
  • Mr. Tyler Jensen, Sr. VP of Engineering & Product Technical Support (Age 52)

What is Scott Mendel's approval rating as GenMark Diagnostics' CEO?

4 employees have rated GenMark Diagnostics CEO Scott Mendel on Glassdoor.com. Scott Mendel has an approval rating of 75% among GenMark Diagnostics' employees.

Who are some of GenMark Diagnostics' key competitors?

What other stocks do shareholders of GenMark Diagnostics own?

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.84%), Price T Rowe Associates Inc. MD (2.61%), William Blair Investment Management LLC (2.05%), Renaissance Technologies LLC (2.04%), Alyeska Investment Group L.P. (1.95%) and Alyeska Investment Group L.P. (1.95%). Company insiders that own GenMark Diagnostics stock include Alan Baer Maderazo, Brian Andrew Mitchell, Christine Shaw, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Michael Kagnoff, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel and Tyler Jensen.
View institutional ownership trends for GenMark Diagnostics

Which major investors are selling GenMark Diagnostics stock?

GNMK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, New York State Common Retirement Fund, Alyeska Investment Group L.P., Alyeska Investment Group L.P., Wells Fargo & Company MN, Nuveen Asset Management LLC, and Northern Trust Corp. Company insiders that have sold GenMark Diagnostics company stock in the last year include Alan Baer Maderazo, Brian Andrew Mitchell, Christine Shaw, Eric Stier, John Frederick Ek, Michael Gleeson, Michael John Harkins, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel, and Tyler Jensen.
View insider buying and selling activity for GenMark Diagnostics
or view top insider-selling stocks.

Which major investors are buying GenMark Diagnostics stock?

GNMK stock was bought by a variety of institutional investors in the last quarter, including Samjo Capital LLC, Blue Water Life Science Advisors LLC, Paradigm Capital Management Inc. NY, William Blair Investment Management LLC, BlackRock Inc., First Trust Advisors LP, HighTower Advisors LLC, and Cowen Prime Services LLC. Company insiders that have bought GenMark Diagnostics stock in the last two years include Kevin C Oboyle, and Michael Kagnoff.
View insider buying and selling activity for GenMark Diagnostics
or or view top insider-buying stocks.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $19.34.

How much money does GenMark Diagnostics make?

GenMark Diagnostics has a market capitalization of $1.41 billion and generates $88.02 million in revenue each year. The medical equipment provider earns $-47,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does GenMark Diagnostics have?

GenMark Diagnostics employs 618 workers across the globe.

What is GenMark Diagnostics' official website?

The official website for GenMark Diagnostics is www.genmarkdx.com.

Where are GenMark Diagnostics' headquarters?

GenMark Diagnostics is headquartered at 5964 LA PLACE COURT, CARLSBAD CA, 92008.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.